Can This Controversial New Drug Curb Alzheimer’s Disease?
UCSF neurologist Gil Rabinovici, MD, explains the controversy and shares why he thinks Alzheimer’s care is entering a new era “regardless of whether aducanumab proves to be a blockbuster or a bust.”